Introduction: Colorectal cancer is the third most commonly diagnosed cancer worldwide constituting 10% of total cancer cases, it’s the second cause of cancer deaths worldwide. In Egypt colorectal cancer is the ninth most commonly diagnosed cancer. Surgical resection is the only curative treatment for locoregional colon cancer [1]. Adjuvant chemotherapy was found to be beneficial in stage III disease, while in stage II disease its benefit is less certain. We aimed in our work to describe the demographics and clinico-pathological features of patients with stage II colon cancer, whether they received adjuvant chemotherapy or not and the outcome of this population as a part of the NCI experience in the period between January 2013 and December 2018.

Patients and Methods: This retrospective cohort study was conducted at the National Cancer Institute, Cairo University, and included patients diagnosed with stage II colon cancer in the period from January 2013 to December 2018.

Results: A total of 89 patients with stage II colon cancer were included with mean age 50.42 ±13.13 years, 52.8% were below the age of 50, male patients represented 58.4%, right sided tumors were present in 57.1% of patients and 42.9% were in left colon, adjuvant chemotherapy was given to 62.8% of patients, Adjuvant chemotherapy was associated with significant improvement in DFS at 5 years 79.6% vs 62.6% (p 0.036) and OS 92.6% vs 76.4% (p 0.026) compared to surveillance only.

Conclusion: in our study adjuvant chemotherapy was associated with better DFS and OS in patients with stage II colon cancer compared to surveillance only.

Keywords: Colon Cancer; Stage II; Adjuvant; Fluoropyrimidine; Oxaliplatin; High Risk Features; National Cancer Institute

References

1. GLOBOCAN 2020. (n.d.). (2022).
2. Williams E A., et al. “Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms”. The Proceedings of the Nutrition Society1 (2003): 107-115.
3. Win A K., et al. “Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer”. Gastroenterology5 (2014): 1205-1208.
4. Wu S., et al. “Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis”. The American Journal of Medicine6 (2012): 551-9.e5.
5. Yamada A., et al. “Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis”. The Lancet Oncology6 (2018): 758-767.
6. Yamazaki K., et al. “Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial”. Annals of Oncology1 (2021a): 77-84.
7. Yamazaki K., et al. “Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial”. Annals of Oncology : Official Journal of the European Society for Medical Oncology 8 (2021b).
8. Yang D X., et al. “Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009”. Cancer18 (2014): 2893-2901.
9. Yuhara H., et al. “Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?” The American Journal of Gastroenterology11 (2011): 1911-1921; quiz 1922.

Citation

Citation: Fatma Mohamed Ahmed Abouelkasem., et al. “Clinico-Pathological Characteristics and Treatment Outcomes of Patients with Stage II Colon Cancer, Single Institutional Experience”.Acta Scientific Cancer Biology 7.9 (2023): 51-53.

Copyright

Copyright: © 2023 Fatma Mohamed Ahmed Abouelkasem., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.